Tracleer® treatment
This patient is treated for pulmonary arterial hypertension with
Tracleer® (bosentan). The Tracleer® tablets are taken orally at a
dose of 62.5 mg during the first month and 125 mg afterwards,
twice daily.
Warning
Strongly influences the cytochrome P450 system.
On prescription of new medicines this should be taken into
account.
Tracleer®
Film coated tablets of 62.5 mg or 125 mg bosentan monohydrate.
Bosentan is a dual endothelin receptor antagonist binding to both
receptor A and B. It lowers both pulmonary and systemic vascular
resistance resulting in a higher cardiac output with out increasing
heart rate.
108018 E october 2007
Treatment guidelines
Patients may develop abnormal liver function and anaemia. Regular
checking of liver function and haemoglobin level is necessary.
In case of AST or ALT greater than 3 but less than 5 ULN, reduce or
interrupt treatment. In case of AST or ALT greater than 5 ULN,
stop treatment. Often several medications for pulmonary
hypertension are prescribed concomitantly. In case of problems
refer to the product description of all medications to see if they
result from medication interaction, side effects or medication effects.
Immediately contact the patient’s pulmonologist in case of problems.